5-Hydroxytryptamine 2A receptor antagonists as potential treatment for psychiatric disorders

Expert Opinion on Investigational Drugs

Volumn 22, Issue 4, 2013, Pages 411-421

  Mestre, Tiago A ^a   Zurowski, Mateusz ^a   Fox, Susan H ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

5 HT2A receptors; Alzheimer's disease; Antagonist; CYR 10; Depression; Eplivanserin; Glemanserin; Insomnia; Nelotanserin; Parkinson's disease; Partial agonist; Pimavanserin; Pruvanserin; Schizophrenia; Serotonin; Volinanserin

Indexed keywords

ALTANSERIN; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; CYR 101; EPLIVANSERIN; GLEMANSERIN; HALOPERIDOL; LY 2422347; MIANSERIN; MIRTAZAPINE; NEFAZODONE; NELOTANSERIN; NEUROLEPTIC AGENT; PAROXETINE; PIMAVANSERIN; PLACEBO; PRUVANSERIN; QUETIAPINE; RISPERIDONE; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SETOPERONE; TRAZODONE; UNCLASSIFIED DRUG; VOLINANSERIN;

AKATHISIA; ALZHEIMER DISEASE; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; AUTISM; AUTOPSY; BEHAVIOR DISORDER; BINDING AFFINITY; BRAIN FUNCTION; CHRONIC PRIMARY INSOMNIA; DEGENERATIVE DISEASE; DEPRESSION; DNA POLYMORPHISM; DOPAMINERGIC ACTIVITY; DRUG BINDING; DRUG DOSE INCREASE; DRUG WITHDRAWAL; DYSKINESIA; DYSTHYMIA; EATING DISORDER; EXTRAPYRAMIDAL SYMPTOM; FIBROMYALGIA RELATED INSOMNIA; GENERALIZED ANXIETY DISORDER; GENETIC ASSOCIATION; GILLES DE LA TOURETTE SYNDROME; HUMAN; INSOMNIA; LIVER FAILURE; MAJOR DEPRESSION; MENTAL DISEASE; MOOD DISORDER; NEUROIMAGING; NEUROLOGIC DISEASE; OBSESSIVE COMPULSIVE DISORDER; PARANOIA; PARKINSON DISEASE; PARKINSONISM; PATHOPHYSIOLOGY; PHARMACOGENETICS; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR BINDING; REVIEW; SCHIZOPHRENIA; SUICIDE; VISUAL HALLUCINATION;

ALZHEIMER DISEASE; HUMANS; MENTAL DISORDERS; PARKINSON DISEASE; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN ANTAGONISTS;

EID: 84875184288     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2013.769957     Document Type: Review

References (124)

1. Nichols DE, Nichols CD. Serotonin receptors. Chem Rev 2008;108(5):1614-41
2. Berg KA, Maayani S, Goldfarb J, Clarke WP. Pleiotropic behavior of 5-HT2A and 5-HT2C receptor agonists. Ann NY Acad Sci 1998;861:104-10
3. Marner L, Knudsen GM, Madsen K, et al. Longitudinal assessment of cerebral 5-HT2A receptors in normal volunteers. An [18F]-altanserin PET study. Neuroimage 2006;31:T101-1
4. Pike VW. Radioligands for PET studies of central 5-HT receptors and reuptake sites-current status. Nucl Med Biol 1995;22(8):1011-18
5. Sadzot B, Lemaire C, Maquet P, et al. Serotonin 5ht(2) receptor imaging in the human brain using positron emission tomography and a new radioligand, [F-18] altanserin-results in young normal controls. J Cereb Blood Flow Metab 1995;15(5):787-97
6. Ito H, Nyberg S, Halldin C, et al. PET imaging of central 5-HT2A receptors with carbon-11-MDL 100,907. J Nucl Med 1998;39(1):208-14
7. Busatto GF, Pilowsky LS, Costa DC, et al. Initial evaluation of I-123-5-IR91150, a selective 5-HT2A ligand for single-photon emission tomography, in healthy human subjects. Eur J Nucl Med 1997;24(2):119-24
8. Adams KH, Pinborg LH, Svarer C, et al. A database of [F-18]-altanserin binding to 5-HT2A receptors in normal volunteers: normative data and relationship to physiological and demographic variables. Neuroimage 2004;21(3):1105-13
9. Rosier A, Dupont P, Peuskens J, et al. Visualisation of loss of 5-HT2A receptors with age in healthy volunteers using [F-18]altanserin and positron emission tomographic imaging. Psychiatry Res 1996;68(1):11-22
10. Hall H, Farde L, Halldin C, et al. Autoradiographic localization of 5-HT2A receptors in the human brain using (LH)-H-3]M100907 and [C-11]M100907. Synapse 2000;38(4):421-31
11. Huot P, Johnston TH, Darr T, et al. Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations. Mov Disord 2010;25(10):1399-408
12. Glennon RA, Titeler M, McKenney JD. Evidence for 5-Ht2 involvement in the mechanism of action of hallucinogenic agents. Life Sci 1984;35(25):2505-11
13. Titeler M, Lyon RA, Glennon RA. Radioligand binding evidence implicates the Brain 5-Ht2 Receptor as a Site of Action for Lsd and Phenylisopropylamine Hallucinogens. Psychopharmacology (Berl) 1988;94(2):213-16
14. Inayama Y, Yoneda H, Sakai T, et al. Positive association between a DNA sequence variant in the serotonin 2A receptor gene and schizophrenia. Am J Med Genet 1996;67(1):103-5
15. Williams J, McGuffin P, Nothen M, Owen MJ. Meta-analysis of association between the 5-HT2a receptor T102C polymorphism and schizophrenia. EMASS Collaborative Group. European Multicentre Association Study of Schizophrenia. Lancet 1997;349(9060):1221
16. Abdolmaleky HM, Faraone SV, Glatt SJ, Tsuang MT. Meta-analysis of association between the T102C polymorphism of the 5HT2a receptor gene and schizophrenia. Schizophr Res 2004;67(1):53-62
17. Polesskaya OO, Sokolov BP. Differential expression of the "C" and "T" alleles of the 5-HT2A receptor gene in the temporal cortex of normal individuals and schizophrenics. J Neurosci Res 2002;67(6):812-22
18. Fanous AH, Chen X, Wang X, et al. Genetic variation in the serotonin 2A receptor and suicidal ideation in a sample of 270 Irish high-density schizophrenia families. Am J Med Genet B Neuropsychiatr Genet 2009;150B(3):411-17
19. Arranz MJ, Munro J, Sham P, et al. Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response. Schizophr Res 1998;32(2):93-9
20. Masellis M, Basile V, Meltzer HY, et al. Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychopharmacology 1998;19(2):123-32
21. Vehof J, Burger H, Wilffert B, et al. Clinical response to antipsychotic drug treatment: association study of polymorphisms in six candidate genes. Eur Neuropsychopharmacol 2012;22(9):625-31
22. Benmessaoud D, Hamdani N, Boni C, et al. Excess of transmission of the G allele of the-1438A/G polymorphism of the 5-HT2A receptor gene in patients with schizophrenia responsive to antipsychotics. BMC Psychiatry 2008;8:40
23. Basile VS, Ozdemir V, Masellis M, et al. Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia. Mol Psychiatry 2001;6(2):230-4
24. Serretti A, Calati R, Mandelli L, De Ronchi D. Serotonin transporter gene variants and behavior: a comprehensive review. Curr Drug Targets 2006;7(12):1659-69
25. Li DW, Duan Y, He L. Association study of serotonin 2A receptor (5-HT2A) gene with schizophrenia and suicidal behavior using systematic meta-analysis. Biochem Biophys Res Commun 2006;340(3):1006-15
26. Abdolmaleky HM, Faraone SV, Glatt SJ, Tsuang MT. Meta-analysis of association between the T102C polymorphism of the 5HT2a receptor gene and schizophrenia. Schizophr Res 2004;67(1):53-62
27. Burnet PWJ, Eastwood SL, Harrison PJ. 5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacology 1996;15(5):442-55
28. Dean B, Hayes W. Decreased frontal cortical serotonin(2A) receptors in schizophrenia. Schizophr Res 1996;21(3):133-9
29. Laruelle M, Abidargham A, Casanova MF, et al. Selective Abnormalities of Prefrontal Serotonergic Receptors in Schizophrenia-a Postmortem Study. Arch Gen Psychiatry 1993;50(10):810-18
30. Lopez-Figueroa AL, Norton CS, Lopez-Figueroa MO, et al. Serotonin 5-HT1A, 5-HT1B, and 5-HT2A receptor mRNA expression in subjects with major depression, bipolar disorder, and schizophrenia. Biol Psychiatry 2004;55(3):225-33
31. Burnet PWJ, Eastwood SL, Harrison PJ. [H-3]WAY-100635 for 5-HT1A receptor autoradiography in human brain: a comparison with [H-3]8-OH-DPAT and demonstration of increased binding in the frontal cortex in schizophrenia. Neurochem Int 1997;30(6):565-74
32. Hernandez I, Sokolov BP. Abnormalities in 5-HT2A receptor mRNA expression in frontal cortex of chronic elderly schizophrenics with varying histories of neuroleptic treatment. J Neurosci Res 2000;59(2):218-25
33. Singh AN, Barlas C, Saeedi H, Mishra RK. Effect of loxapine on peripheral dopamine-like and serotonin receptors in patients with schizophrenia. J Psychiatry Neurosci 2003;28(1):39-47
34. Trichard C, Paillere-Martinot ML, Attar-Levy D, et al. No serotonin 5-HT2A receptor density abnormality in the cortex of schizophrenic patients studied with PET. Schizophrenia Res 1998;31(1):13-17
35. Lewis R, Kapur S, Jones C, et al. Serotonin 5-HT2 receptors in schizophrenia: a PET study using [F-18] setoperone in neuroleptic-naive patients and normal subjects. Am J Psychiatry 1999;156(1):72-8
36. Verhoeff N, Meyer JH, Kecojevic A, et al. A voxel-by-voxel analysis of [F-18] setoperone PET data shows no substantial serotonin 5-HT2A receptor changes in schizophrenia. Psychiatry Res 2000;99(3):123-35
37. Rasmussen H, Erritzoe D, Andersen R, et al. Decreased frontal serotonin(2A) receptor Binding in antipsychotic-naive patients with first-episode schizophrenia. Arch Gen Psychiatry 2010;67(1):9-16
38. Hurlemann R, Boy C, Meyer PT, et al. Decreased prefrontal 5-HT2A receptor binding in subjects at enhanced risk for schizophrenia. Anat Embryol (Berl) 2005;210(5-6):519-23
39. Meltzer HY, Matsubara S, Lee JC. Classification of Typical and Atypical Antipsychotic-Drugs on the Basis of Dopamine D-1, D-2 and Serotonin2 Pki Values. J Pharmacol Exp Ther 1989;251(1):238-46
40. Meltzer HY. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 1999;21(2):S106-15
41. Travis MJ, Busatto GF, Pilowsky LS, et al. 5-HT2A receptor blockade in patients with schizophrenia treated with risperidone or clozapine-A SPET study using the novel 5-HT2A ligand I-123-5-I-R-91150. Br J Psychiatry 1998;173:236-41
42. Rasmussen H, Ebdrup BH, Erritzoe D, et al. Serotonin2A receptor blockade and clinical effect in first-episode schizophrenia patients treated with quetiapine. Psychopharmacology (Berl) 2011;213(2-3):583-92
43. Tyson PJ, Roberts KH, Mortimer AM. Are the cognitive effects of atypical antipsychotics influenced by their affinity to 5HT-2A receptors? Int J Neurosci 2004;114(6):593-611
44. Lai MK, Tsang SW, Esiri MM, et al. Serotonin 5-HT2A receptor alterations in the postmortem neocortex of behaviorally assessed Alzheimer patients. J Neurochem 2003;87:106-6
45. Hasselbalch SG, Madsen K, Svarer C, et al. Reduced 5-HT2A receptor binding in patients with mild cognitive impairment. Neurobiol Aging 2008;29(12):1830-8
46. Santhosh L, Estok KM, Vogel RS, et al. Regional distribution and behavioral correlates of 5-HT2A receptors in Alzheimer's disease with [F-18] deuteroaltanserin and PET. Psychiatry Res 2009;173(3):212-17
47. Marner L, Frokjaer VG, Kalbitzer J, et al. Loss of serotonin 2A receptors exceeds loss of serotonergic projections in early Alzheimer's disease: a combined [C-11]DASB and [F-18]altanserin-PET study. Neurobiol Aging 2012;33(3):479-87
48. Holmes C, Arranz MJ, Powell JF, et al. 5-HT2A and 5-HT2C receptor polymorphisms and psychopathology in late onset Alzheimer's disease. Hum Mol Gen 1998;7(9):1507-9
49. Assal F, Alarcon M, Solomon EC, et al. Association of the serotonin transporter and receptor gene polymorphisms in neuropsychiatric symptoms in Alzheimer disease. Arch Neurol 2004;61:8,1249-53
50. Nacmias B, Tedde A, Forleo P, et al. Association between 5-HT2A receptor polymorphism and psychotic symptoms in Alzheimer's disease. Biol Psychiatry 2001;50(6):472-5
51. Rocchi A, Micheli D, Ceravolo R, et al. Serotoninergic polymorphisms (5-HTTLPR and 5-HT2A): association studies with psychosis in Alzheimer disease. Genet Test Win 2003;7(4):309-14
52. Holmes C, Arranz M, Collier D, et al. Depression in Alzheimer's disease: the effect of serotonin receptor gene variation. Am JMed Genet Part B 2003;119B(1):40-3
53. Ramanathan S, Glatt SJ. Serotonergic system genes in psychosis of Alzheimer dementia: meta-analysis. Am J Geriatr Psychiatry 2009;17(10):839-46
54. Micheli D, Bonvicini C, Rocchi A, et al. No evidence for allelic association of serotonin 2A receptor and transporter gene polymorphisms with depression in Alzheimer disease. J Alzheimers Dis 2006;10(4):371-8
55. Craig D, Donnelly C, Hart D, et al. Analysis of the 5HT-2A T102C receptor polymorphism and psychotic symptoms in Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet 2007;144B(1):126-8
56. Wilkosz PA, Kodavali C, Weamer EA, et al. Prediction of psychosis onset in Alzheimer disease: the role of depression symptom severity and the HTR2A T102C polymorphism. Am J Med Genet B Neuropsychiatr Genet 2007;144B(8):1054-62
57. Fernandez HH, Donnelly EM, Friedman JH. Long-term outcome of clozapine use for psychosis in parkinsonian patients. Mov Disord 2004;19(7):831-3
58. Pollak P, Tison F, Rascol O, et al. Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry 2004;75(5):689-95
59. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002;47(1):27-38
60. Ballanger B, Strafella AP, van Eimeren T, et al. Serotonin 2A receptors and visual hallucinations in Parkinson disease. Arch Neurol 2010;67(4):416-21
61. Kiferle L, Ceravolo R, Petrozzi L, et al. Visual hallucinations in Parkinson's disease are not influenced by polymorphisms of serotonin 5-HT2A receptor and transporter genes. Neurosci Lett 2007;422(3):228-31
62. Anguelova M, Benkelfat C, Turecki G. A systematic review of association studies investigating genes coding for serotonin receptors the serotonin transporter: I. Affective disorders. Mol Psychiatry 2003;8(6):574-91
63. Kumar HB, Purushottam M, Kubendran S, et al. Serotonergic candidate genes and puerperal psychosis: an association study. Psychiatr Genet 2007;17(5):253-60
64. Mintun MA, Sheline YI, Moerlein SM, et al. Decreased hippocampal 5-HT2A receptor binding in major depressive disorder: in vivo measurement with [18F]altanserin positron emission tomography. Biol Psychiatry 2004;55(3):217-24
65. Sheline YI, Mintun MA, Barch DM, et al. Decreased hippocampal 5-HT(2A) receptor binding in older depressed patients using [18F]altanserin positron emission tomography. Neuropsychopharmacology 2004;29(12):2235-41
66. McMahon FJ, Buervenich S, Charney D, et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet 2006;78(5):804-14
67. Sato K, Yoshida K, Takahashi H, et al. Association between-1438G/A promoter polymorphism in the 5-HT2A receptor gene and fluvoxamine response in Japanese patients with major depressive disorder. Neuropsychobiology 2002;46(3):136-40
68. Wilkie MJ, Smith G, Day RK, et al. Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy. Pharmacogenomics J 2009;9(1):61-70
69. Choi MJ, Kang RH, Ham BJ, et al. Serotonin receptor 2A gene polymorphism (-1438A/G) and short-term treatment response to citalopram. Neuropsychobiology 2005;52(3):155-62
70. Frokjaer VG, Vinberg M, Erritzoe D, et al. Familial risk for mood disorder and the personality risk factor, neuroticism, interact in their association with frontolimbic serotonin 2A receptor binding. Neuropsychopharmacology 2010;35(5):1129-37
71. Frokjaer VG, Mortensen EL, Nielsen FA, et al. Frontolimbic serotonin 2A receptor binding in healthy subjects is associated with personality risk factors for affective disorder. Biol Psychiatry 2008;63(6):569-76
72. Hrdina PD, Demeter E, Vu TB, et al. 5-HT uptake sites and 5-ht2 receptors in brain of antidepressant-free suicide victims depressives-increase in 5-ht2 sites in cortex and amygdala. Brain Res 1993;614:1-2
73. Pandey GN, Dwivedi Y, Rizavi HS, et al. Higher expression of serotonin 5-HT2A receptors in the postmortem brains of teenage suicide victims. Am J Psychiatry 2002;159(3):419-29
74. Escriba PV, Ozaita A, Garcia-Sevilla JA. Increased mRNA expression of alpha (2A)-adrenoceptors, serotonin receptors and mu-opioid receptors in the brains of suicide victims. Neuropsychopharmacology 2004;29(8):1512-21
75. Audenaert K, Van Laere K, Dumont F, et al. Decreased frontal serotonin 5-HT2a receptor binding index in deliberate self-harm patients. Eur J Nucl Med 2001;28(2):175-82
76. Asberg M, Traskman L, Thoren P. 5-HIAA IN Cerebrospinal-Fluid-Biochemical Suicide Predictor. Arch Gen Psychiatry 1976;33(10):1193-7
77. Du LS, Bakish D, Lapierre YD, et al. Association of polymorphism of serotonin 2A receptor gene with suicidal ideation in major depressive disorder. Am J Med Genet 2000;96(1):56-60
78. Anguelova M, Benkelfat C, Turecki G. A systematic review of association studies investigating genes coding for serotonin receptors and the serotonin transporter: II. Suicidal behavior. Mol Psychiatry 2003;8(7):646-53
79. Bandelow B, Zohar J, Hollander E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders-first revision. World J Biol Psychiatry 2008;9(4):248-312
80. Yoon HK, Yang JC, Lee HJ, Kim YK. The association between serotonin-related gene polymorphisms and panic disorder. J Anxiety Disord 2008;22(8):1529-34
81. Unschuld PG, Ising M, Erhardt A, et al. Polymorphisms in the serotonin receptor gene HTR2A are associated with quantitative traits in panic disorder. Am J Med Genet B Neuropsychiatr Genet 2007;144B(4):424-9
82. Lohoff FW, Narasimhan S, Rickels K. Interaction between polymorphisms in serotonin transporter (SLC6A4) and serotonin receptor 2A (HTR2A) genes predict treatment response to venlafaxine XR in generalized anxiety disorder. Pharmacogenomics J 2012 doi: 10.1038/tpj.2012.33. [Epub ahead of print]
83. Lohoff FW, Aquino TD, Narasimhan S, et al. Serotonin receptor 2A (HTR2A) gene polymorphism predicts treatment response to venlafaxine XR in generalized anxiety disorder. Pharmacogenomics J 2013;13(1):21-6
84. Enoch MA, Kaye WH, Rotondo A, et al. 5-HT2A promoter polymorphism-1438G/ A, anorexia nervosa, and obsessive-compulsive disorder. Lancet 1998;351(9118):1785-6
85. Saiz PA, Garcia-Portilla MP, Arango C, et al. Association study between obsessive-compulsive disorder and serotonergic candidate genes. Prog Neuropsychopharmacol Biol Psychiatry 2008;32(3):765-70
86. Denys D, Van Nieuwerburgh F, Deforce D, Westenberg HG. Prediction of response to paroxetine and venlafaxine by serotonin-related genes in obsessive-compulsive disorder in a randomized, double-blind trial. J Clin Psychiatry 2007;68(5):747-53
87. Perani D, Garibotto V, Gorini A, et al. In vivo PET study of 5HT(2A) serotonin and D(2) dopamine dysfunction in drug-naive obsessive-compulsive disorder. Neuroimage 2008;42(1):306-14
88. Adams KH, Hansen ES, Pinborg LH, et al. Patients with obsessive-compulsive disorder have increased 5-HT2A receptor binding in the caudate nuclei. Int J Neuropsychopharmacol 2005;8(3):391-401
89. Schwartz MW, Woods SC, Porte D Jr, et al. Central nervous system control of food intake. Nature 2000;404(6778):661-71
90. Audenaert K, Van Laere K, Dumont F, et al. Decreased 5-HT2a receptor binding in patients with anorexia nervosa. J Nucl Med 2003;44:2
91. Frank GK, Kaye WH, Meltzer CC, et al. Reduced 5-HT2A receptor binding after recovery from anorexia nervosa. Biol Psychiatry 2002;52:9
92. Bailer UF, Price JC, Meltzer CC, et al. Altered 5-HT(2A) receptor binding after recovery from bulimia-type anorexia nervosa: relationships to harm avoidance and drive for thinness. Neuropsychopharmacology 2004;29(6):1143-55
93. Bailer UF, Kaye WH. Serotonin: imaging findings in eating disorders. Curr Top Behav Neurosci 2011;6:59-79
94. Erritzoe D, Frokjaer VG, Haugbol S, et al. Brain serotonin 2A receptor binding: relations to body mass index, tobacco and alcohol use. Neuroimage 2009;46(1):23-30
95. Ziegler A, Hebebrand J, Gorg T, et al. Further lack of association between the 5-HT2A gene promoter polymorphism and susceptibility to eating disorders and a meta-analysis pertaining to anorexia nervosa. Mol Psychiatry 1999;4(5):410-12
96. Kipman A, Bruins-Slot L, Boni C, et al. 5-HT(2A) gene promoter polymorphism as a modifying rather than a vulnerability factor in anorexia nervosa. Eur Psychiatry 2002;17(4):227-9
97. Gorwood P, Ades J, Bellodi L, et al. The 5-HT(2A)-1438G/A polymorphism in anorexia nervosa: a combined analysis of 316 trios from six European centres. Mol Psychiatry 2002;7(1):90-4
98. Haugbol S, Pinborg LH, Regeur L, et al. Cerebral 5-HT2A receptor binding is increased in patients with Tourette's syndrome. Int J Neuropsychopharmacol 2007;10(2):245-52
99. Gizer IR, Ficks C, Waldman ID. Candidate gene studies of ADHD: a meta-analytic review. Hum Genet 2009;126(1):51-90
100. Beversdorf DQ, Nordgren RE, Bonab AA, et al. 5-HT2 receptor distribution shown by [18F] setoperone PET in high-functioning autistic adults. J Neuropsychiatry Clin Neurosci 2012;24(2):191-7
101. Girgis RR, Slifstein M, Xu X, et al. The 5-HT2A receptor and serotonin transporter in Asperger's Disorder: a PET study with [C-11]MDL 100907 and [C-11]DASB. Psychiatry Res 2011;194(3):230-4
102. Seppi K, Weintraub D, Coelho M, et al. The Movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson's disease. Mov Disord 2011;26(Suppl 3):S42-80
103. Bossini L, Casolaro I, Koukouna D, et al. Off-label uses of trazodone: a review. Expert Opin Pharmacother 2012;13(12):1707-17
104. Canada H. Discontinuation Of Sales Of Nefazodone In Canada. Available from: http://www.hc-sc.gc.ca/dhp-mps/alt-formats/hpfb-dgpsa/pdf/medeff/ linnefazodone-hpc-cps-eng.pdf
105. Bonnier C, Nassogne MC, Evrard P. Ketanserin treatment of Tourette's syndrome in children. Am J Psychiatry 1999;156(7):1122-3
106. Vanover KE, Weiner DM, Makhay M, et al. Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2- methylpropyloxy)phen ylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist. J Pharmacol Exp Ther 2006;317(2):910-18
107. Meltzer HY, Elkis H, Vanover K, et al. Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day. Schizophr Res 2012;141(2-3):144-52
108. Ebdrup BH, Rasmussen H, Arnt J, Glenthoj B. Serotonin 2A receptor antagonists for treatment of schizophrenia. [Review]. Expert Opin Investig Drugs 2011;20(9):1211-23
109. Mills R, Revell S, Bahr D, et al. A double-blind, placebo-controlled, dose-escalation trial of pimavanserin in Parkinson's disease and psychosis. Mov Disord 2008;23(1):S221-2
110. Mills R, Bahr D, Williams H. Optimization of phase III study design for pimavanserin in the treatment of Parkinson's disease psychosis. WFN XIX World Congress on Parkinson's disease and related disorders. Volume 18 Parkinsonism and Related Disorders; Shanghai, China; 2012. p. S81-S159
111. Inc. AP. ACADIA Announces Pimavanserin Meets Primary and Key Secondary Endpoints in Pivotal Phase III Parkinson's Disease Psychosis Trial. Available from: http://phx.corporate-ir. net/phoenix.zhtml?c=125180&p=irolnewsArticle- print&ID=1761922& highlight [Accessed 27 November 2012]
112. Price DL, Bonhaus DW, McFarland K. Pimavanserin, a 5-HT2A receptor inverse agonist, reverses psychosis-like behaviors in a rodent model of Alzheimer's disease. Behav Pharmacol 2012;23(4):426-33
113. Ancoli-Israel S, Vanover KE, Weiner DM, et al. Pimavanserin tartrate, a 5-HT(2A) receptor inverse agonist, increases slow wave sleep as measured by polysomnography in healthy adult volunteers. Sleep Med 2011;12(2):134-41
114. Vanover KE, Betz AJ, Weber SM, et al. A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model. Pharmacol Biochem Behav 2008;90(4):540-4
115. Meltzer HY, Arvanitis L, Bauer D, Rein W; Meta-Trial Study G. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am J Psychiatry 2004;161(6):975-84
116. Sanofi-Aventis. Eplivanserin-Clinical Study Results. 2012. Available from: http://en.sanofi.com/rd/clinical-trials/our-commitments/clinical-study- results.aspx-para-6 [Accessed November 2012]
117. Efficacy and Safety of SR46349B in Patients With Sleep Disorders in Fibromyalgia. November 29, 2010; April 7, 2006
118. FDA. Drugs@FDA. Available from: http://www.accessdata.fda.gov/scripts/ cder/drugsatfda/index.cfm? fuseaction=Search.DrugDetails [Accessed 20 November 2012]
119. Arena Pharmaceuticals I. Nelotanserin Program. 2012.Available from: http://www. arenapharm.com/nelotanserin.aspx [Accessed August 2012]
120. Sramek JJ, Robinson RE, Suri A, Cutler NR. Efficacy trial of the 5-HT2 antagonist MDL 11,939 in patients with generalized anxiety disorder. J Clin Psychopharmacol 1995;15(1):20-2
121. ClinicalTrials.gov. Vol 2012: U.S. National Institute of Health; 2012
122. Talbot PS, Slifstein M, Hwang DR, et al. Extended characterisation of the serotonin 2A (5-HT2A) receptor-selective PET radiotracer 11C-MDL100907 in humans: quantitative analysis, test-retest reproducibility, and vulnerability to endogenous 5-HT tone. Neuroimage 2012;59(1):271-85
123. Teegarden BR, Al Shamma H, Xiong YF. 5-HT2A inverse-agonists for the treatment of insomnia. Curr Top Med Chem 2008;8(11):969-76
124. Tzavara ET, Bymaster FP, Davis RJ, et al. M4 muscarinic receptors regulate the dynamics of cholinergic and dopaminergic neurotransmission: relevance to the pathophysiology and treatment of related CNS pathologies. Faseb J 2004;18(12):1410-12